Correlation Between Esperion Therapeutics and Neurocrine Biosciences

Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Esperion Therapeutics and Neurocrine Biosciences, you can compare the effects of market volatilities on Esperion Therapeutics and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Neurocrine Biosciences.

Diversification Opportunities for Esperion Therapeutics and Neurocrine Biosciences

0.72

Correlation Coefficient

Esperion Therapeutics  Neurocrine Biosciences

Poor diversification

The 3 months correlation between Esperion and Neurocrine is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Neurocrine Biosciences

Given the investment horizon of 90 days Esperion Therapeutics is expected to under-perform the Neurocrine Biosciences. In addition to that, Esperion Therapeutics is 1.3 times more volatile than Neurocrine Biosciences. It trades about -0.14 of its total potential returns per unit of risk. Neurocrine Biosciences is currently generating about -0.1 per unit of volatility. If you would invest  13,706  in Neurocrine Biosciences on December 30, 2024 and sell it today you would lose (2,390) from holding Neurocrine Biosciences or give up 17.44% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Esperion Therapeutics  vs.  Neurocrine Biosciences

Esperion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Neurocrine Biosciences

Risk-Adjusted Performance

Very Weak

Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Esperion Therapeutics and Neurocrine Biosciences

The main advantage of trading using opposite Esperion Therapeutics and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.

The idea behind Esperion Therapeutics and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.